News Biden plan would axe interchangeable status for biosimilars President Joe Biden’s budget proposal for fiscal 2025 includes a proposal that would allow pharmacy substitution of biosimilar drugs for the reference product, even if the
News Samsung seeks 'interchangeable' label for Humira biosimilar While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's
Partner Content Partner Content Four Key Reasons to Attend SMi's 2019 Biosimilars Conference Four Key Reasons to Attend SMi's 2019 Biosimilars
Partner Content Partner Content Michel Mikhail invites Biosimilar experts to attend SMi’s 10... Michel Mikhail invites Biosimilar experts to attend SMi
Partner Content Partner Content Save the date for SMi’s 10th Annual Biosimilars Conference 2... Save the date for SMi’s 10th Annual Biosimilars Conf
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.